ScripDuring the latest round of quarterly sales and earnings updates, drug manufacturers have signaled they are well positioned to absorb the cost of tariffs, but those assurances might be cold comfort to
Pink SheetDuring the latest round of quarterly sales and earnings updates, drug manufacturers signaled they are well positioned to absorb the cost of tariffs, but the assurances may be cold comfort to investors
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly To Discover, Develop Oligonucleo
In VivoWhen Michael Davidson, CEO of NewAmsterdam Pharma, describes his company’s lead asset obicetrapib, he frames it as a solution to one of cardiology’s most persistent challenges: managing residual cardi